Clinical Trial Update: Randomized Phase II Study of Hepatitis C Immune Globulin Intravenous (Human), Civacir(TM), in Liver Transplantation [Phase 2]

View source ↗

Summary

A randomized Phase II trial evaluating Civacir (hepatitis C immune globulin intravenous) in liver transplant recipients was terminated; results were posted in 2…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Liver Transplantation
• Sequelae of Viral Hepatitis

Drugs mentioned

• Civacir (polyclonal immune globulin (IgG))

Snippet

Sponsor: ADMA Biologics, Inc. | Conditions: Sequelae of Viral Hepatitis, Transplantation Infection | Phase 2 | Status: TERMINATED | Results posted: 2012-02-07